CN103622988A - 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 - Google Patents
虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 Download PDFInfo
- Publication number
- CN103622988A CN103622988A CN201210302951.5A CN201210302951A CN103622988A CN 103622988 A CN103622988 A CN 103622988A CN 201210302951 A CN201210302951 A CN 201210302951A CN 103622988 A CN103622988 A CN 103622988A
- Authority
- CN
- China
- Prior art keywords
- cordycepin
- depression
- medicine
- drug
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 title claims abstract description 103
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 title claims abstract description 97
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 title claims abstract description 97
- 239000000935 antidepressant agent Substances 0.000 title abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 52
- 230000000694 effects Effects 0.000 claims abstract description 27
- 229930182470 glycoside Natural products 0.000 claims abstract description 11
- 150000002338 glycosides Chemical class 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 10
- 241001597008 Nomeidae Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000001430 anti-depressive effect Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 19
- 229940005513 antidepressants Drugs 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 229960004801 imipramine Drugs 0.000 description 14
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 14
- 230000009182 swimming Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 241000581650 Ivesia Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000190633 Cordyceps Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 208000017194 Affective disease Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
- 229960002102 imipramine hydrochloride Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210302951.5A CN103622988B (zh) | 2012-08-23 | 2012-08-23 | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 |
CN201610829002.0A CN106265713B (zh) | 2012-08-23 | 2012-08-23 | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 |
PCT/CN2013/081295 WO2014029285A1 (zh) | 2012-08-23 | 2013-08-12 | 虫草素在制备抗抑郁症药物中的用途 |
US14/423,084 US9629866B2 (en) | 2012-08-23 | 2013-08-12 | Use of cordycepin in manufacture of medicaments for anti-depression |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210302951.5A CN103622988B (zh) | 2012-08-23 | 2012-08-23 | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610829002.0A Division CN106265713B (zh) | 2012-08-23 | 2012-08-23 | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103622988A true CN103622988A (zh) | 2014-03-12 |
CN103622988B CN103622988B (zh) | 2016-08-17 |
Family
ID=50149423
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210302951.5A Active CN103622988B (zh) | 2012-08-23 | 2012-08-23 | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 |
CN201610829002.0A Active CN106265713B (zh) | 2012-08-23 | 2012-08-23 | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610829002.0A Active CN106265713B (zh) | 2012-08-23 | 2012-08-23 | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9629866B2 (zh) |
CN (2) | CN103622988B (zh) |
WO (1) | WO2014029285A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115501245B (zh) * | 2022-10-12 | 2023-10-31 | 西安萱御制药集团有限公司 | 抗产道细胞损伤促弹性蛋白合成的组分及应用 |
CN116478225A (zh) * | 2023-04-12 | 2023-07-25 | 南京工业大学 | 一种丝氨酸改性的虫草素磷酸酯药物分子的制备方法与应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101984975A (zh) * | 2010-10-29 | 2011-03-16 | 北京润德康医药技术有限公司 | 一种含虫草素衍生物的药用组合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3277077A (en) * | 1964-06-03 | 1966-10-04 | Merck & Co Inc | 3-deoxy ribofuranosyl halides |
JPS5455596A (en) * | 1977-10-05 | 1979-05-02 | Yamasa Shoyu Co Ltd | Cordycepin derivative and its preparation |
WO2005030231A1 (fr) * | 2003-09-28 | 2005-04-07 | Shaosheng Sun | Extraction de l'aweto, fabrication et utilisation |
WO2007067559A2 (en) * | 2005-12-06 | 2007-06-14 | Regents Of The University Of Minnesota | Antibacterial agents |
KR100799116B1 (ko) * | 2006-09-26 | 2008-01-29 | 건국대학교 산학협력단 | 코디세핀을 함유하는 비만 치료 및 예방제용 약학 조성물 |
CN101716196B (zh) * | 2009-12-04 | 2012-03-21 | 华南师范大学 | 虫草素提取物和在制备降血糖药物或保健食品中的应用 |
CN101985457A (zh) * | 2010-10-29 | 2011-03-16 | 北京润德康医药技术有限公司 | 虫草素药用盐及其制备方法、医药用途 |
KR101208290B1 (ko) * | 2010-11-22 | 2012-12-05 | 인제대학교 산학협력단 | 코르디세핀 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 퇴행성 신경질환 치료 또는 예방용 약학조성물 |
-
2012
- 2012-08-23 CN CN201210302951.5A patent/CN103622988B/zh active Active
- 2012-08-23 CN CN201610829002.0A patent/CN106265713B/zh active Active
-
2013
- 2013-08-12 WO PCT/CN2013/081295 patent/WO2014029285A1/zh active Application Filing
- 2013-08-12 US US14/423,084 patent/US9629866B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101984975A (zh) * | 2010-10-29 | 2011-03-16 | 北京润德康医药技术有限公司 | 一种含虫草素衍生物的药用组合物 |
Non-Patent Citations (1)
Title |
---|
王茂水等: "冬虫夏草生物活性的研究进展", 《北方园艺》, no. 07, 15 July 2009 (2009-07-15) * |
Also Published As
Publication number | Publication date |
---|---|
CN103622988B (zh) | 2016-08-17 |
CN106265713B (zh) | 2019-10-22 |
CN106265713A (zh) | 2017-01-04 |
US20150209380A1 (en) | 2015-07-30 |
US9629866B2 (en) | 2017-04-25 |
WO2014029285A1 (zh) | 2014-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
WO2016107579A1 (zh) | 黄酮醇作为脑靶向增效剂的制备和应用 | |
CN103860530A (zh) | 虾青素作为抗抑郁症药物的用途 | |
CN103622988B (zh) | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 | |
CN106038534B (zh) | 冬凌草甲素在制备抗抑郁症药物中的用途 | |
CN103860578A (zh) | 香菇多糖作为抗抑郁症药物的用途 | |
CN105796538A (zh) | 白藜芦醇及其类似物作为hiv潜伏病毒库激活剂的应用 | |
CN106038522A (zh) | 大黄酸在制备抗抑郁症药物中的用途 | |
Ravshanova et al. | Studies of acute toxicity of the drug" Analfenon" for use in tablet form | |
CN104000820B (zh) | 盐酸去亚甲基小檗碱在制备预防和/或治疗溃疡性结肠炎药物中的应用 | |
CN101066278B (zh) | 能量合剂的医药用途 | |
CN105919991B (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
CN104288684A (zh) | 治疗精神分裂症的药物组合物 | |
CN105434422A (zh) | α-和γ-倒捻子素在制备抗抑郁药物中的应用 | |
CN115337308B (zh) | Acss2抑制剂在制备抗h1n1亚型猪流感病毒药物中的应用 | |
Hassan et al. | Emergency Available Drugs in Markets to Treat COVID-19 | |
CN105617069B (zh) | 一种用于调节双相情感障碍疾病的口服液及其制备方法 | |
CN105311387B (zh) | 复方手参丸在制备治疗原发性震颤药物中的应用 | |
CN101411700B (zh) | 5,7,4'-三羟基二氢黄酮或其衍生物用于止痛的用途 | |
CN100441202C (zh) | 晕痛定药物及其生产工艺 | |
CN104771388B (zh) | 一种药物制剂及其在制备治疗抑郁症与肠炎药物中的应用 | |
Ozcete et al. | Cardiac arrest due to a lethal dose of propafenone and first case to survive following treatment with intravenous fat emulsion | |
CN116036102A (zh) | 曼那斯汀降低xelox联合治疗方案导致的肠道损伤的应用 | |
CN101919854B (zh) | 小唐松草醛碱作为制备治疗心律失常药物的应用 | |
CN104800640A (zh) | 一种治疗精神抑郁症的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220606 Address after: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee after: Luo Yongqiang Address before: Room b273, building 1, No. 39, shengshengyuan Road, Science Park, Changping District, Beijing 102206 Patentee before: BEIJING GRAGEN BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231204 Address after: Floor 3, Building 402, Zone 1, Tiantong Dongyuan, Dongxiaokou Town, Changping District, Beijing, 102218 Patentee after: Beijing Yasheng Bohou Biotechnology Development Center Address before: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee before: Luo Yongqiang |